{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T03:37:15Z","timestamp":1775187435169,"version":"3.50.1"},"reference-count":197,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T00:00:00Z","timestamp":1729641600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.clml.2024.10.012","type":"journal-article","created":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T16:46:29Z","timestamp":1729701989000},"page":"e151-e172","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["First Line Treatment of Newly Diagnosed Transplant Eligible Multiple Myeloma Recommendations From a Canadian Consensus Guideline Consortium"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0325-3401","authenticated-orcid":false,"given":"Sahar","family":"Khan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Debra J.","family":"Bergstrom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"C\u00f4t\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rami","family":"Kotb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"LeBlanc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martha L.","family":"Louzada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hira S.","family":"Mian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ibraheem","family":"Othman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriele","family":"Colasurdo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alissa","family":"Visram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.clml.2024.10.012_bib0001","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1056\/NEJM199607113350204","article-title":"A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Fran\u00e7ais du My\u00e9lome","volume":"335","author":"Attal","year":"1996","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.clml.2024.10.012_bib0002","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1056\/NEJMoa022340","article-title":"High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma","volume":"348","author":"Child","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2024.10.012_bib0003","doi-asserted-by":"crossref","first-page":"3755","DOI":"10.1182\/blood-2005-03-1301","article-title":"High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA","volume":"106","author":"Blade","year":"2005","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.clml.2024.10.012_bib0004","first-page":"2687","article-title":"Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321 [published correction appears","volume":"24","author":"Barlogie","year":"2006","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.clml.2024.10.012_bib0005","doi-asserted-by":"crossref","first-page":"e456","DOI":"10.1016\/S2352-3026(20)30099-5","volume":"7","author":"Cavo","year":"2020","journal-title":"Lancet Haematol"},{"issue":"8","key":"10.1016\/j.clml.2024.10.012_bib0006","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1182\/blood-2012-02-408922","article-title":"Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA\/GEM study","volume":"120","author":"Rosi\u00f1ol","year":"2012","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.clml.2024.10.012_bib0007","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/S1470-2045(21)00535-0","volume":"22","author":"Gay","year":"2021","journal-title":"Lancet Oncol"},{"issue":"14","key":"10.1016\/j.clml.2024.10.012_bib0008","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.clml.2024.10.012_bib0009","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2204925","article-title":"Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma","volume":"387","author":"Richardson","year":"2022","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.clml.2024.10.012_bib0010","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1001\/jamaoncol.2017.4600","article-title":"Autologous Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction: a Systematic Review and Meta-analysis","volume":"4","author":"Dhakal","year":"2018","journal-title":"JAMA Oncol"},{"issue":"23","key":"10.1016\/j.clml.2024.10.012_bib0011","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1182\/blood-2018-06-858613","article-title":"Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma","volume":"132","author":"Perrot","year":"2018","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2024.10.012_bib0012","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S1470-2045(22)00693-3","volume":"24","author":"Mina","year":"2023","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.clml.2024.10.012_bib0013","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1182\/blood-2012-01-405985","article-title":"Clonal competition with alternating dominance in multiple myeloma","volume":"120","author":"Keats","year":"2012","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.clml.2024.10.012_bib0014","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.3109\/10428194.2012.751528","article-title":"Early versus delayed autologous stem cell transplant in patients receiving novel therapies for multiple myeloma","volume":"54","author":"Dunavin","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"10.1016\/j.clml.2024.10.012_bib0015","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1002\/cncr.26422","article-title":"Early versus delayed autologous transplantation after immunomodulatory agents-based induction therapy in patients with newly diagnosed multiple myeloma","volume":"118","author":"Kumar","year":"2012","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.clml.2024.10.012_bib0016","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.transproceed.2015.12.031","article-title":"Early Versus Delayed Autologous Stem Cell Transplantation and Interferon Maintenance in Multiple Myeloma: single-Center Experience of 18 Years","volume":"48","author":"Remenyi","year":"2016","journal-title":"Transplant Proc"},{"issue":"23","key":"10.1016\/j.clml.2024.10.012_bib0017","doi-asserted-by":"crossref","first-page":"5077","DOI":"10.1002\/cncr.33171","article-title":"Age no bar: a CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myeloma","volume":"126","author":"Munshi","year":"2020","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.clml.2024.10.012_bib0018","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/bjh.18025","article-title":"Trends in autologous stem cell transplantation for newly diagnosed multiple myeloma: changing demographics and outcomes in European Society for Blood and Marrow Transplantation centres from 1995 to 2019","volume":"197","author":"Swan","year":"2022","journal-title":"Br J Haematol"},{"issue":"9594","key":"10.1016\/j.clml.2024.10.012_bib0019","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/S0140-6736(07)61537-2","article-title":"Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial","volume":"370","author":"Facon","year":"2007","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.clml.2024.10.012_bib0020","doi-asserted-by":"crossref","first-page":"231","DOI":"10.3324\/haematol.2020.262360","article-title":"Autologous stem cell transplantation is safe and effective for fit older myeloma patients: exploratory results from the Myeloma XI trial","volume":"107","author":"Pawlyn","year":"2022","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.clml.2024.10.012_bib0021","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1038\/bmt.2016.174","article-title":"Autologous stem cell transplant for multiple myeloma patients 70 years or older","volume":"51","author":"Muchtar","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.clml.2024.10.012_bib0022","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1093\/annonc\/mdt509","article-title":"Autologous stem cell transplantation for elderly patients with newly diagnosed multiple myeloma in the era of novel agents","volume":"25","author":"Merz","year":"2014","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.clml.2024.10.012_bib0023","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s00277-018-3528-x","article-title":"Real-life data on safety and efficacy of autologous stem cell transplantation in elderly patients with multiple myeloma","volume":"98","author":"Marini","year":"2019","journal-title":"Ann Hematol"},{"issue":"1","key":"10.1016\/j.clml.2024.10.012_bib0024","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jgo.2019.05.014","article-title":"Autologous stem cell transplant in older patients (age \u2265 65) with newly diagnosed multiple myeloma: a systematic review and meta-analysis","volume":"11","author":"Mian","year":"2020","journal-title":"J Geriatr Oncol"},{"issue":"36","key":"10.1016\/j.clml.2024.10.012_bib0025","doi-asserted-by":"crossref","first-page":"6086","DOI":"10.1200\/JCO.2009.22.2232","article-title":"VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA study","volume":"27","author":"Dimopoulos","year":"2009","journal-title":"J Clin Oncol"},{"issue":"30","key":"10.1016\/j.clml.2024.10.012_bib0026","doi-asserted-by":"crossref","first-page":"4635","DOI":"10.1200\/JCO.2010.28.1238","article-title":"Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study","volume":"28","author":"Ludwig","year":"2010","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.clml.2024.10.012_bib0027","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/j.1600-0609.2009.01385.x","article-title":"Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA","volume":"84","author":"Morabito","year":"2010","journal-title":"Eur J Haematol"},{"issue":"6","key":"10.1016\/j.clml.2024.10.012_bib0028","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/s41409-018-0122-8","article-title":"Extending autologous transplantation as first line therapy in multiple myeloma patients with severe renal impairment: a retrospective study by the SFGM-TC","volume":"53","author":"Augeul-Meunier","year":"2018","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"10.1016\/j.clml.2024.10.012_bib0029","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.bbmt.2009.03.021","article-title":"Autologous hematopoietic stem cell transplantation may reverse renal failure in patients with multiple myeloma","volume":"15","author":"Parikh","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.clml.2024.10.012_bib0030","first-page":"182","article-title":"Impact of Autologous Stem Cell Transplantation on Blood Pressure and Renal Function in Multiple Myeloma Patients","volume":"109","author":"Balsam","year":"2017","journal-title":"J Natl Med Assoc"},{"issue":"10","key":"10.1016\/j.clml.2024.10.012_bib0031","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/sj.bmt.1704948","article-title":"Melphalan 200 mg\/m2 with blood stem cell support as first-line myeloma therapy: impact of glomerular filtration rate on engraftment, transplantation-related toxicity and survival","volume":"35","author":"Carlson","year":"2005","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"10.1016\/j.clml.2024.10.012_bib0032","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1038\/bmt.2017.198","article-title":"Autologous hematopoietic cell transplantation for multiple myeloma patients with renal insufficiency: a center for international blood and marrow transplant research analysis","volume":"52","author":"Mahindra","year":"2017","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.clml.2024.10.012_bib0033","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/sj.thj.6200003","article-title":"Are myeloma patients with renal failure candidates for autologous stem cell transplantation?","volume":"1","author":"San Miguel","year":"2000","journal-title":"Hematol J"},{"issue":"8","key":"10.1016\/j.clml.2024.10.012_bib0034","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1016\/j.bbmt.2015.04.004","article-title":"Prospective Validation of the Predictive Power of the Hematopoietic Cell Transplantation Comorbidity Index: a Center for International Blood and Marrow Transplant Research Study","volume":"21","author":"Sorror","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"10.1016\/j.clml.2024.10.012_bib0035","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1016\/j.bbmt.2017.06.014","article-title":"Hematopoietic Cell Transplantation-Specific Comorbidity Index Predicts Morbidity and Mortality in Autologous Stem Cell Transplantation","volume":"23","author":"Berro","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.clml.2024.10.012_bib0036","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.bbmt.2013.12.557","article-title":"Hematopoietic cell transplant comorbidity index is predictive of survival after autologous hematopoietic cell transplantation in multiple myeloma","volume":"20","author":"Saad","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"10.1016\/j.clml.2024.10.012_bib0037","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/j.bbmt.2008.06.019","article-title":"Utility of comorbidity assessment in predicting transplantation-related toxicity following autologous hematopoietic stem cell transplantation for multiple myeloma","volume":"14","author":"Labont\u00e9","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"10.1016\/j.clml.2024.10.012_bib0038","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.clml.2023.01.016","article-title":"First Line Treatment of Newly Diagnosed Transplant Ineligible Multiple Myeloma: recommendations from the Canadian Myeloma Research Group Consensus Guideline Consortium","volume":"23","author":"C\u00f4t\u00e9","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"5","key":"10.1016\/j.clml.2024.10.012_bib0039","doi-asserted-by":"crossref","first-page":"910","DOI":"10.3324\/haematol.2016.162693","article-title":"A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients","volume":"102","author":"Engelhardt","year":"2017","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.clml.2024.10.012_bib0040","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1038\/s41375-021-01488-8","article-title":"Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA","volume":"36","author":"Facon","year":"2022","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.clml.2024.10.012_bib0041","doi-asserted-by":"crossref","first-page":"616","DOI":"10.3324\/haematol.2011.051441","article-title":"Benefit from autologous stem cell transplantation in primary refractory myeloma? Different outcomes in progressive versus stable disease","volume":"97","author":"Rosi\u00f1ol","year":"2012","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.clml.2024.10.012_bib0042","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1182\/blood-2009-07-235531","article-title":"Stem cell transplantation in multiple myeloma: impact of response failure with thalidomide or lenalidomide induction","volume":"115","author":"Gertz","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.10.012_bib0043","doi-asserted-by":"crossref","first-page":"4135","DOI":"10.1182\/blood.V118.21.4135.4135","article-title":"Increased bone marrow plasma cell infiltration pre-transplant is associated with worse outcomes in patients undergoing high dose chemotherapy and autologous stem cell transplantation for multiple myeloma","volume":"118","author":"Shah","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.10.012_bib0044","doi-asserted-by":"crossref","first-page":"4119","DOI":"10.1182\/blood.V118.21.4119.4119","article-title":"Response before autologous hematopoietic stem cell transplantation is an important predictor of outcome in multiple myeloma","volume":"118","author":"Farhan","year":"2011","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.clml.2024.10.012_bib0045","doi-asserted-by":"crossref","first-page":"e616","DOI":"10.1016\/S2352-3026(19)30167-X","article-title":"Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial","volume":"6","author":"Jackson","year":"2019","journal-title":"Lancet Haematol"},{"issue":"1","key":"10.1016\/j.clml.2024.10.012_bib0046","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1182\/hematology.2021000229","article-title":"High-risk multiple myeloma: how to treat at diagnosis and relapse?","volume":"2021","author":"Mateos","year":"2021","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.clml.2024.10.012_bib0047","unstructured":"Kaiser M. Depth of response and MRD status in ultra high-risk myeloma and plasma cell leukemia treated with Dara-CVRd and augmented autologous transplant: results of the risk-stratified UK OPTIMUM\/MUKnine trial. Available at: https:\/\/library.ehaweb.org\/eha\/2021\/eha2021-virtual-congress\/324589\/martin.kaiser.depth.of.response.and.mrd.status.in.ultra.high-risk.myeloma.and.html. Accessed October 30, 2023."},{"issue":"3","key":"10.1016\/j.clml.2024.10.012_bib0048","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-046225","volume":"11","author":"Brown","year":"2021","journal-title":"BMJ Open"},{"issue":"1","key":"10.1016\/j.clml.2024.10.012_bib0049","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1200\/JCO.23.01696","article-title":"Isatuximab, carfilzomib, lenalidomide, and dexamethasone for the treatment of high-risk newly diagnosed multiple myeloma","volume":"42","author":"Leypoldt","year":"2024","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clml.2024.10.012_bib0050","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1016\/S2352-3026(20)30354-9","article-title":"Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial","volume":"8","author":"Usmani","year":"2021","journal-title":"Lancet Haematol"},{"issue":"10","key":"10.1016\/j.clml.2024.10.012_bib0051","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S1470-2045(23)00405-9","article-title":"Treatment of primary plasma cell leukaemia with carfilzomib and lenalidomide-based therapy (EMN12\/HOVON-129): final analysis of a non-randomised, multicentre, phase 2 study","volume":"24","author":"van de Donk","year":"2023","journal-title":"Lancet Oncol"},{"issue":"10192","key":"10.1016\/j.clml.2024.10.012_bib0052","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study [published correction appears","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.clml.2024.10.012_bib0053","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"390","author":"Sonneveld","year":"2024","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.clml.2024.10.012_bib0054","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1200\/JCO.18.00776","article-title":"Development and validation of a cytogenetic prognostic index predicting survival in multiple myeloma","volume":"37","author":"Perrot","year":"2019","journal-title":"J Clin Oncol"},{"issue":"26","key":"10.1016\/j.clml.2024.10.012_bib0055","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised International Staging System for multiple myeloma: a report from International Myeloma Working Group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clml.2024.10.012_bib0056","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/s41375-018-0196-8","article-title":"A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis","volume":"33","author":"Walker","year":"2019","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.clml.2024.10.012_bib0057","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1182\/blood-2006-03-009910","article-title":"Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation","volume":"108","author":"Hanamura","year":"2006","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.clml.2024.10.012_bib0058","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1182\/blood-2010-04-279596","article-title":"A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value","volume":"116","author":"Walker","year":"2010","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.clml.2024.10.012_bib0059","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41408-019-0254-0","article-title":"Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone","volume":"9","author":"Schmidt","year":"2019","journal-title":"Blood Cancer J"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2024.10.012_bib0060","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1182\/blood-2020-139689","article-title":"Is tandem ASCT needed in MM patients with high risk cytogenetics in the era of maintenance therapy? Results from the Canadian Myeloma Research Group (CMRG) database","volume":"136","author":"Duggan","year":"2020","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.clml.2024.10.012_bib0061","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1182\/blood-2014-03-565051","article-title":"Trends in survival of patients with primary plasma cell leukemia: a population-based analysis","volume":"124","author":"Gonsalves","year":"2014","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clml.2024.10.012_bib0062","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1182\/blood.V93.3.1032","article-title":"Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics","volume":"93","author":"Garc\u00eda-Sanz","year":"1999","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2024.10.012_bib0063","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1038\/leu.2012.336","article-title":"Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group","volume":"27","author":"Fern\u00e1ndez de Larrea","year":"2013","journal-title":"Leukemia"},{"issue":"suppl 1","key":"10.1016\/j.clml.2024.10.012_bib0064","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1182\/blood-2020-137075","article-title":"Poor prognosis of multiple myeloma predicted by high levels of circulating plasma cells is independent from other high-risk features but is modulated by the achievement of minimal residual disease negativity","volume":"136","author":"Bertamini","year":"2020","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.clml.2024.10.012_bib0065","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.3324\/haematol.2016.158303","article-title":"Prognostic impact of circulating plasma cells in patients with multiple myeloma: implications for plasma cell leukemia definition","volume":"102","author":"Granell","year":"2017","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.clml.2024.10.012_bib0066","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41408-018-0065-8","article-title":"Defining cure in multiple myeloma: a comparative study of outcomes of young individuals with myeloma and curable hematologic malignancies","volume":"8","author":"Ravi","year":"2018","journal-title":"Blood Cancer J"},{"issue":"11","key":"10.1016\/j.clml.2024.10.012_bib0067","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.3324\/haematol.2012.065698","article-title":"Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents","volume":"97","author":"Usmani","year":"2012","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.clml.2024.10.012_bib0068","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.3324\/haematol.2021.280568","article-title":"Comparison of autologous and allogeneic hematopoietic cell transplantation strategies in patients with primary plasma cell leukemia, with dynamic prediction modeling","volume":"108","author":"Lawless","year":"2023","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.clml.2024.10.012_bib0069","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1038\/s41375-021-01233-1","article-title":"Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era","volume":"35","author":"Dhakal","year":"2021","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.clml.2024.10.012_bib0070","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/leu.2013.241","article-title":"Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia","volume":"28","author":"Musto","year":"2014","journal-title":"Leukemia"},{"issue":"18","key":"10.1016\/j.clml.2024.10.012_bib0071","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1200\/JCO.2015.63.1929","article-title":"Bortezomib, doxorubicin, cyclophosphamide, dexamethasone induction followed by stem cell transplantation for primary plasma cell leukemia: a prospective phase II study of the Intergroupe Francophone du My\u00e9lome","volume":"34","author":"Royer","year":"2016","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.clml.2024.10.012_bib0072","doi-asserted-by":"crossref","first-page":"5752","DOI":"10.1182\/blood-2011-05-355081","article-title":"Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma","volume":"118","author":"Moreau","year":"2011","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2024.10.012_bib0073","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood-2012-02-408898","article-title":"Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma","volume":"120","author":"Cavo","year":"2012","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.clml.2024.10.012_bib0074","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1182\/blood-2016-01-693580","article-title":"VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial","volume":"127","author":"Moreau","year":"2016","journal-title":"Blood"},{"issue":"15_suppl","key":"10.1016\/j.clml.2024.10.012_bib0075","doi-asserted-by":"crossref","first-page":"8003","DOI":"10.1200\/JCO.2017.35.15_suppl.8003","article-title":"Carfilzomib-lenalidomide-dexamethasone (KRd) vs carfilzomib-cyclophosphamide-dexamethasone (KCd) induction: planned interim analysis of the randomized FORTE trial in newly diagnosed multiple myeloma (NDMM)","volume":"35","author":"Gay","year":"2020","journal-title":"J Clin Oncol"},{"issue":"suppl_1","key":"10.1016\/j.clml.2024.10.012_bib0076","doi-asserted-by":"crossref","first-page":"3245","DOI":"10.1182\/blood-2018-99-112659","article-title":"Integrated analysis of randomized controlled trials evaluating bortezomib + lenalidomide + dexamethasone or bortezomib + thalidomide + dexamethasone induction in transplant-eligible newly diagnosed multiple myeloma","volume":"132","author":"Dachs","year":"2018","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.clml.2024.10.012_bib0077","doi-asserted-by":"crossref","first-page":"e825","DOI":"10.1016\/S2352-3026(23)00217-X","article-title":"Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial","volume":"10","author":"Voorhees","year":"2023","journal-title":"Lancet Haematol"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2024.10.012_bib0078","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1182\/blood-2023-177546","article-title":"Results of the phase III randomized IsKia Trial: isatuximab-carfilzomib-lenalidomide-dexamethasone vs carfilzomib-lenalidomide-dexamethasone as pre-transplant induction and post-transplant consolidation in newly diagnosed multiple myeloma patients","volume":"142","author":"Gay","year":"2023","journal-title":"Blood"},{"issue":"suppl_1","key":"10.1016\/j.clml.2024.10.012_bib0079","doi-asserted-by":"crossref","first-page":"4767","DOI":"10.1182\/blood-2021-153632","article-title":"A phase 2 multi-center, open label study of Isatuximab added to standard Cybord induction and lenalidomide maintenance treatments in newly diagnosed, transplant eligible multiple myeloma","volume":"138","author":"Kotb","year":"2021","journal-title":"Blood"},{"issue":"suppl_1","key":"10.1016\/j.clml.2024.10.012_bib0080","doi-asserted-by":"crossref","first-page":"4751","DOI":"10.1182\/blood-2023-190168","volume":"142","author":"Kotb","year":"2023","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.clml.2024.10.012_bib0081","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJM198405243102104","article-title":"Effective treatment of advanced multiple myeloma refractory to alkylating agents","volume":"310","author":"Barlogie","year":"1984","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.clml.2024.10.012_bib0082","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/bjh.15244","article-title":"Impact of duration of induction therapy on survival in newly diagnosed multiple myeloma patients undergoing upfront autologous stem cell transplantation","volume":"182","author":"Chakraborty","year":"2018","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.clml.2024.10.012_bib0083","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.bbmt.2014.10.023","article-title":"Impact of pretransplant therapy and depth of disease response before autologous transplantation for multiple myeloma","volume":"21","author":"Vij","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.clml.2024.10.012_bib0084","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/s41408-023-00905-8","article-title":"Real-world results of autologous stem cell transplantation in newly diagnosed multiple myeloma: a report from the Canadian Myeloma Research Group database","volume":"13","author":"C\u00f4t\u00e9","year":"2023","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2024.10.012_bib0085","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1182\/asheducation-2003.1.419","article-title":"Stem cell mobilization","author":"Cottler-Fox","year":"2003","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"10","key":"10.1016\/j.clml.2024.10.012_bib0086","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1200\/JCO.1995.13.10.2547","article-title":"Factors that influence collection and engraftment of autologous peripheral-blood stem cells","volume":"13","author":"Bensinger","year":"1995","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.clml.2024.10.012_bib0087","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1038\/leu.2009.127","article-title":"International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100)","volume":"23","author":"Giralt","year":"2009","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.clml.2024.10.012_bib0088","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.bbmt.2013.10.013","article-title":"Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations","volume":"20","author":"Giralt","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"10.1016\/j.clml.2024.10.012_bib0089","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1182\/blood-2009-04-205013","article-title":"Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens","volume":"114","author":"Kumar","year":"2009","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.clml.2024.10.012_bib0090","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s00277-020-04376-w","article-title":"Comparison of the efficiency, safety, and survival outcomes in two stem cell mobilization regimens with cyclophosphamide plus G-CSF or G-CSF alone in multiple myeloma: a meta-analysis","volume":"100","author":"Wang","year":"2021","journal-title":"Ann Hematol"},{"issue":"3","key":"10.1016\/j.clml.2024.10.012_bib0091","doi-asserted-by":"crossref","first-page":"244.e1","DOI":"10.1016\/j.jtct.2020.12.009","article-title":"Low-dose cyclophosphamide versus intermediate-high-dose cyclophosphamide versus granulocyte colony-stimulating factor alone for stem cell mobilization in multiple myeloma in the era of novel agents: a multicenter Retrospective Study","volume":"27","author":"Zannetti","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"23","key":"10.1016\/j.clml.2024.10.012_bib0092","doi-asserted-by":"crossref","first-page":"5720","DOI":"10.1182\/blood-2008-08-174946","article-title":"Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma","volume":"113","author":"DiPersio","year":"2009","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2024.10.012_bib0093","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1038\/s41591-023-02273-z","article-title":"Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial","volume":"29","author":"Crees","year":"2023","journal-title":"Nat Med"},{"issue":"9","key":"10.1016\/j.clml.2024.10.012_bib0094","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1038\/sj.leu.2404801","article-title":"Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma","volume":"21","author":"Kumar","year":"2007","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.clml.2024.10.012_bib0095","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1007\/s00520-013-1808-5","article-title":"Evaluating the effects of lenalidomide induction therapy on peripheral stem cells collection in patients undergoing autologous stem cell transplant for multiple myeloma","volume":"21","author":"Bhutani","year":"2013","journal-title":"Support Care Cancer"},{"issue":"5","key":"10.1016\/j.clml.2024.10.012_bib0096","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.bbmt.2019.11.024","article-title":"Impact of plerixafor use at different peripheral blood cd34+ thresholds on autologous stem cell collection in patients with multiple myeloma","volume":"26","author":"Shah","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"10.1016\/j.clml.2024.10.012_bib0097","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1038\/leu.2011.131","article-title":"Stem cell mobilization in patients with newly diagnosed multiple myeloma after lenalidomide induction therapy","volume":"25","author":"Cavallo","year":"2011","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.clml.2024.10.012_bib0098","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.bbmt.2009.02.011","article-title":"Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma","volume":"15","author":"Popat","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"10.1016\/j.clml.2024.10.012_bib0099","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1038\/bmt.2012.60","article-title":"Growth factor plus preemptive ('just-in-time') plerixafor successfully mobilizes hematopoietic stem cells in multiple myeloma patients despite prior lenalidomide exposure","volume":"47","author":"Costa","year":"2012","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"10.1016\/j.clml.2024.10.012_bib0100","doi-asserted-by":"crossref","first-page":"e716","DOI":"10.1016\/j.clml.2022.03.013","article-title":"Prolonged lenalidomide induction does not significantly impair stem cell collection in multiple myeloma patients mobilized with cyclophosphamide or plerixafor: a report from the covid era","volume":"22","author":"Rybinski","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"8","key":"10.1016\/j.clml.2024.10.012_bib0101","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.3324\/haematol.2020.261842","article-title":"Stem cell yield and transplantation in transplant-eligible newly diagnosed multiple myeloma patients receiving daratumumab + bortezomib\/thalidomide\/dexamethasone in the phase 3 CASSIOPEIA study","volume":"106","author":"Hulin","year":"2021","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.clml.2024.10.012_bib0102","doi-asserted-by":"crossref","first-page":"174.e1","DOI":"10.1016\/j.jtct.2022.11.029","article-title":"Stem cell mobilization yields with daratumumab- and lenalidomide-containing quadruplet induction therapy in newly diagnosed multiple myeloma: findings from the MASTER and GRIFFIN Trials","volume":"29","author":"Chhabra","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"3","key":"10.1016\/j.clml.2024.10.012_bib0103","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1046\/j.1365-2141.2003.04107.x","article-title":"Mobilization of CD34+ cells in elderly patients (>\/= 70 years) with multiple myeloma: influence of age, prior therapy, platelet count and mobilization regimen","volume":"120","author":"Morris","year":"2003","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1016\/j.clml.2024.10.012_bib0104","first-page":"846","article-title":"Oral melphalan at diagnosis hampers adequate collection of peripheral blood progenitor cells in multiple myeloma","volume":"87","author":"Boccadoro","year":"2002","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.clml.2024.10.012_bib0105","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.jtct.2022.03.019","article-title":"ASTCT clinical practice recommendations for transplantation and cellular therapies in multiple myeloma","volume":"28","author":"Dhakal","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"36","key":"10.1016\/j.clml.2024.10.012_bib0106","doi-asserted-by":"crossref","first-page":"9227","DOI":"10.1200\/JCO.2005.03.0551","article-title":"High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe","volume":"23","author":"Fermand","year":"2005","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.clml.2024.10.012_bib0107","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1182\/blood.V99.3.731","volume":"99","author":"Moreau","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.10.012_bib0108","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/978-3-642-46836-0_4","article-title":"Peripheral blood progenitor cell transplantation in multiple myeloma following high-dose melphalan-based therapy","volume":"144","author":"Goldschmidt","year":"1998","journal-title":"Recent Results Cancer Res"},{"key":"10.1016\/j.clml.2024.10.012_bib0109","doi-asserted-by":"crossref","first-page":"4625","DOI":"10.1182\/blood-2018-99-112045","article-title":"Full dose or reduced dose melphalan (MEL) for autologous stem cell transplantation (ASCT) in multiple myeloma (MM): a single center analysis on 187 consecutive patients","volume":"132","author":"Brioli","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.10.012_bib0110","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1182\/blood-2009-09-241737","article-title":"Melphalan 200 mg\/m2 versus melphalan 100 mg\/m2 in newly diagnosed myeloma patients: a prospective, multicenter phase 3 study","volume":"115","author":"Palumbo","year":"2010","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2024.10.012_bib0111","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1186\/s12935-021-02313-z","article-title":"Long-term outcomes of busulfan plus melphalan-based versus melphalan 200 mg\/m2 conditioning regimens for autologous hematopoietic stem cell transplantation in patients with multiple myeloma: a systematic review and meta-analysis","volume":"21","author":"Gao","year":"2021","journal-title":"Cancer Cell Int"},{"issue":"8","key":"10.1016\/j.clml.2024.10.012_bib0112","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1016\/j.bbmt.2016.03.021","article-title":"Busulfan, melphalan, and bortezomib versus high-dose melphalan as a conditioning regimen for autologous hematopoietic stem cell transplantation in multiple myeloma","volume":"22","author":"Rodriguez","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"18","key":"10.1016\/j.clml.2024.10.012_bib0113","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1182\/blood.2021014635","article-title":"Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study","volume":"139","author":"Roussel","year":"2022","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.clml.2024.10.012_bib0114","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1038\/s41409-022-01681-y","article-title":"Adding bendamustine to melphalan before ASCT improves CR rate in myeloma vs. melphalan alone: a randomized phase-2 trial","volume":"57","author":"Farag","year":"2022","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"10.1016\/j.clml.2024.10.012_bib0115","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1200\/JCO.2009.23.7172","article-title":"Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma","volume":"28","author":"Ladetto","year":"2010","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.clml.2024.10.012_bib0116","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1182\/blood.2020008733","article-title":"How I treat high-risk multiple myeloma","volume":"139","author":"Zamagni","year":"2022","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.clml.2024.10.012_bib0117","doi-asserted-by":"crossref","first-page":"e427","DOI":"10.1016\/S2352-3026(20)30110-1","article-title":"Intensification and consolidation therapy in multiple myeloma in the current era","volume":"7","author":"Nadeem","year":"2020","journal-title":"Lancet Haematol"},{"issue":"32","key":"10.1016\/j.clml.2024.10.012_bib0118","doi-asserted-by":"crossref","first-page":"3613","DOI":"10.1200\/JCO.21.01045","article-title":"Consolidation and maintenance in newly diagnosed multiple myeloma","volume":"39","author":"Sonneveld","year":"2021","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.clml.2024.10.012_bib0119","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1200\/JCO.18.00685","article-title":"Autologous transplantation, consolidation, and maintenance therapy in multiple myeloma: results of the BMT CTN 0702 Trial","volume":"37","author":"Stadtmauer","year":"2019","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.clml.2024.10.012_bib0120","first-page":"e528","article-title":"Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"5","author":"Dimopoulos","year":"2021","journal-title":"Hemasphere"},{"issue":"19","key":"10.1016\/j.clml.2024.10.012_bib0121","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1182\/blood.2020008735","article-title":"How I treat frontline transplantation-eligible multiple myeloma","volume":"139","author":"Perrot","year":"2022","journal-title":"Blood"},{"issue":"suppl 15","key":"10.1016\/j.clml.2024.10.012_bib0122","doi-asserted-by":"crossref","first-page":"8506","DOI":"10.1200\/JCO.2020.38.15_suppl.8506","article-title":"Long-term follow-up of BMT CTN 0702 (STa- MINA) of postautologous hematopoietic cell transplantation (autoHCT) strategies in the upfront treatment of multiple myeloma (MM) [abstract]","volume":"38","author":"Hari","year":"2020","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.clml.2024.10.012_bib0123","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1056\/NEJM197910043011402","article-title":"The chemotherapy of plasma-cell myeloma and the incidence of acute leukemia","volume":"301","author":"Bergsagel","year":"1979","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.clml.2024.10.012_bib0124","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/bjc.1988.17","article-title":"A randomized trial of maintenance versus no maintenance melphalan and prednisone in responding multiple myeloma patients","volume":"57","author":"Belch","year":"1988","journal-title":"Br J Cancer"},{"issue":"2","key":"10.1016\/j.clml.2024.10.012_bib0125","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/j.1365-2141.2006.06405.x","article-title":"A randomised comparison of melphalan with prednisone or dexamethasone as induction therapy and dexamethasone or observation as maintenance therapy in multiple myeloma: NCIC CTG MY.7","volume":"136","author":"Shustik","year":"2007","journal-title":"Br J Haematol"},{"issue":"9","key":"10.1016\/j.clml.2024.10.012_bib0126","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1200\/JCO.1995.13.9.2354","article-title":"Randomized trial of interferon maintenance in multiple myeloma: a study of the National Cancer Institute of Canada Clinical Trials Group","volume":"13","author":"Browman","year":"1995","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.clml.2024.10.012_bib0127","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1182\/blood-2012-09-451872","article-title":"A randomized phase 3 trial of thalidomide and prednisone as maintenance therapy after ASCT in patients with MM with a quality-of-life assessment: the National Cancer Institute of Canada Clinicals Trials Group Myeloma 10 Trial","volume":"121","author":"Stewart","year":"2013","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2024.10.012_bib0128","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(09)70284-0","article-title":"Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial","volume":"11","author":"Rajkumar","year":"2010","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.clml.2024.10.012_bib0129","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa1402551","article-title":"Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma","volume":"371","author":"Benboubker","year":"2014","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.clml.2024.10.012_bib0130","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1056\/NEJMoa070596","article-title":"Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America","volume":"357","author":"Weber","year":"2007","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.clml.2024.10.012_bib0131","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa070594","article-title":"Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma","volume":"357","author":"Dimopoulos","year":"2007","journal-title":"N Engl J Med"},{"issue":"29","key":"10.1016\/j.clml.2024.10.012_bib0132","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1200\/JCO.2017.72.6679","article-title":"Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: a Meta-Analysis","volume":"35","author":"McCarthy","year":"2017","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.clml.2024.10.012_bib0133","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1001\/jamaoncol.2018.2961","article-title":"Maintenance Treatment and Survival in Patients With Myeloma: a Systematic Review and Network Meta-analysis","volume":"4","author":"Gay","year":"2018","journal-title":"JAMA Oncol"},{"issue":"24","key":"10.1016\/j.clml.2024.10.012_bib0134","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1200\/JCO.2011.39.6820","article-title":"Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65\/GMMG-HD4 trial","volume":"30","author":"Sonneveld","year":"2012","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.clml.2024.10.012_bib0135","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/leu.2017.211","article-title":"Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65\/GMMG-HD4 trial","volume":"32","author":"Goldschmidt","year":"2018","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.clml.2024.10.012_bib0136","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1182\/blood-2011-09-379164","article-title":"Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p","volume":"119","author":"Neben","year":"2012","journal-title":"Blood"},{"issue":"10168","key":"10.1016\/j.clml.2024.10.012_bib0137","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0140-6736(18)33003-4","article-title":"Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"393","author":"Dimopoulos","year":"2019","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.clml.2024.10.012_bib0138","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1038\/s41375-022-01691-1","article-title":"Ixazomib, lenalidomide and dexamethasone consolidation with randomized ixazomib or lenalidomide maintenance after autologous transplant in newly diagnosed multiple myeloma","volume":"36","author":"Slade","year":"2022","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.clml.2024.10.012_bib0139","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S1470-2045(22)00738-0","article-title":"Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial","volume":"24","author":"Dytfeld","year":"2023","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.clml.2024.10.012_bib0140","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1016\/S1470-2045(21)00428-9","volume":"22","author":"Moreau","year":"2021","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.clml.2024.10.012_bib0141","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1038\/leu.2013.335","article-title":"Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients","volume":"28","author":"Nooka","year":"2014","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.clml.2024.10.012_bib0142","doi-asserted-by":"crossref","first-page":"752.e1","DOI":"10.1016\/j.jtct.2022.07.028","article-title":"Lenalidomide-based maintenance after autologous hematopoietic stem cell transplantation for patients with high-risk multiple myeloma","volume":"28","author":"Pasvolsky","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"14","key":"10.1016\/j.clml.2024.10.012_bib0143","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1182\/blood.2022018339","article-title":"Optimizing the value of lenalidomide maintenance by extended genetic profiling: an analysis of 556 patients in the Myeloma XI trial","volume":"141","author":"Panopoulou","year":"2023","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clml.2024.10.012_bib0144","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1038\/leu.2013.335","article-title":"Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients","volume":"28","author":"Nooka","year":"2014","journal-title":"Leukemia"},{"issue":"19","key":"10.1016\/j.clml.2024.10.012_bib0145","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1056\/NEJMoa1114083","article-title":"Lenalidomide after stem-cell transplantation for multiple myeloma","volume":"366","author":"McCarthy","year":"2012","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.clml.2024.10.012_bib0146","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1056\/NEJMoa1402888","article-title":"Autologous transplantation and maintenance therapy in multiple myeloma","volume":"371","author":"Palumbo","year":"2014","journal-title":"N Engl J Med"},{"issue":"suppl_1","key":"10.1016\/j.clml.2024.10.012_bib0147","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1182\/blood-2022-165376","article-title":"Defining the optimal duration of lenalidomide maintenance after autologous stem cell transplant - data from the myeloma XI Trial","volume":"140","author":"Pawlyn","year":"2022","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.clml.2024.10.012_bib0148","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1182\/blood.2022019531","article-title":"Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma","volume":"142","author":"Rosi\u00f1ol","year":"2023","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.clml.2024.10.012_bib0149","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1056\/NEJMoa1114138","article-title":"Lenalidomide maintenance after stem-cell transplantation for multiple myeloma","volume":"366","author":"Attal","year":"2012","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.clml.2024.10.012_bib0150","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(18)30687-9","article-title":"Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial","volume":"20","author":"Jackson","year":"2019","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.clml.2024.10.012_bib0151","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.3324\/haematol.2020.247130","article-title":"Lenalidomide before and after autologous stem cell transplantation for transplant-eligible patients of all ages in the randomized, phase III, Myeloma XI trial","volume":"106","author":"Jackson","year":"2021","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.clml.2024.10.012_bib0152","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1177\/10781552221150935","article-title":"Predictors of lenalidomide maintenance duration after autologous stem cell transplant in patients with multiple myeloma","volume":"29","author":"Rath","year":"2023","journal-title":"J Oncol Pharm Pract"},{"issue":"1","key":"10.1016\/j.clml.2024.10.012_bib0153","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1016\/j.clml.2021.07.028","article-title":"Management of myeloma manifestations and complications: the Cornerstone of Supportive Care: recommendation of the Canadian Myeloma Research Group (formerly Myeloma Canada Research Network) Consensus Guideline Consortium","volume":"22","author":"LeBlanc","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"8","key":"10.1016\/j.clml.2024.10.012_bib0154","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1111\/imj.16100","article-title":"Executive summary of consensus clinical practice guidelines for the prevention of infection in patients with multiple myeloma","volume":"53","author":"Teh","year":"2023","journal-title":"Intern Med J"},{"issue":"2","key":"10.1016\/j.clml.2024.10.012_bib0155","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S2352-3026(21)00283-0","article-title":"Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group","volume":"9","author":"Raje","year":"2022","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2024.10.012_bib0156","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.blre.2019.01.001","article-title":"Management of infectious complications in multiple myeloma patients: expert panel consensus-based recommendations","volume":"34","author":"Girmenia","year":"2019","journal-title":"Blood Rev"},{"issue":"2","key":"10.1016\/j.clml.2024.10.012_bib0157","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s00277-020-04297-8","volume":"100","author":"Christopeit","year":"2021","journal-title":"Ann Hematol"},{"issue":"36","key":"10.1016\/j.clml.2024.10.012_bib0158","doi-asserted-by":"crossref","first-page":"9219","DOI":"10.1200\/JCO.2005.03.2086","article-title":"Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United kingdom Medical Research Council trials between 1980 and 2002\u2013Medical Research Council Adult Leukaemia Working Party","volume":"23","author":"Augustson","year":"2005","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.clml.2024.10.012_bib0159","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/S1470-2045(19)30506-6","article-title":"Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial","volume":"20","author":"Drayson","year":"2019","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.clml.2024.10.012_bib0160","doi-asserted-by":"crossref","first-page":"e198","DOI":"10.1016\/j.bbmt.2020.03.027","article-title":"Fluoroquinolone Prophylaxis in Autologous Stem Cell Transplantation: worthy of a Second Look","volume":"26","author":"Maakaron","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"36","key":"10.1016\/j.clml.2024.10.012_bib0161","doi-asserted-by":"crossref","first-page":"9219","DOI":"10.1200\/JCO.2005.03.2086","article-title":"Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United kingdom Medical Research Council trials between 1980 and 2002\u2013Medical Research Council Adult Leukaemia Working Party","volume":"23","author":"Augustson","year":"2005","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.clml.2024.10.012_bib0162","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1056\/NEJM199203263261301","article-title":"A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation","volume":"326","author":"Goodman","year":"1992","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.clml.2024.10.012_bib0163","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1086\/422312","article-title":"Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation","volume":"39","author":"van Burik","year":"2004","journal-title":"Clin Infect Dis"},{"issue":"7","key":"10.1016\/j.clml.2024.10.012_bib0164","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.3109\/10428194.2015.1106538","article-title":"Antiviral prophylaxis for varicella zoster virus infections in patients with myeloma in the era of novel therapies","volume":"57","author":"Teh","year":"2016","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"10.1016\/j.clml.2024.10.012_bib0165","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/bmt.2009.263","article-title":"Vaccination of hematopoietic cell transplant recipients","volume":"44","author":"Ljungman","year":"2009","journal-title":"Bone Marrow Transplant"},{"issue":"23","key":"10.1016\/j.clml.2024.10.012_bib0166","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1182\/blood-2015-12-550475","article-title":"How I vaccinate blood and marrow transplant recipients","volume":"127","author":"Carpenter","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.10.012_bib0167","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101983","article-title":"SARS-CoV-2 vaccination in the first year after allogeneic hematopoietic cell transplant: a prospective, multicentre, observational study","volume":"59","author":"Hill","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"18","key":"10.1016\/j.clml.2024.10.012_bib0168","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1200\/JCO.21.02372","article-title":"Trends in late mortality and life expectancy after autologous blood or marrow transplantation over three decades: a BMTSS Report","volume":"40","author":"Bhatia","year":"2022","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.clml.2024.10.012_bib0169","doi-asserted-by":"crossref","first-page":"4753","DOI":"10.1182\/blood-2012-11-466961","article-title":"Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma","volume":"121","author":"Usmani","year":"2013","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.clml.2024.10.012_bib0170","doi-asserted-by":"crossref","first-page":"4086","DOI":"10.1182\/blood-2011-05-355743","article-title":"Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS)","volume":"118","author":"Mailankody","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.10.012_bib0171","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/1471-2407-11-83","article-title":"The relative risk of second primary cancers in Queensland, Australia: a retrospective cohort study","volume":"11","author":"Youlden","year":"2011","journal-title":"BMC Cancer"},{"issue":"4","key":"10.1016\/j.clml.2024.10.012_bib0172","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.bbmt.2014.12.028","article-title":"New cancers after autotransplantations for multiple myeloma","volume":"21","author":"Mahindra","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2024.10.012_bib0173","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.leukres.2018.07.016","article-title":"Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma","volume":"74","author":"Radivoyevitch","year":"2018","journal-title":"Leuk Res"},{"issue":"7","key":"10.1016\/j.clml.2024.10.012_bib0174","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1038\/leu.2014.22","article-title":"Update on second primary malignancies in multiple myeloma: a focused review","volume":"28","author":"Landgren","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2024.10.012_bib0175","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/801495","article-title":"Secondary primary malignancies in multiple myeloma: an old NEMESIS revisited","volume":"2012","author":"Yang","year":"2012","journal-title":"Adv Hematol"},{"issue":"suppl_1","key":"10.1016\/j.clml.2024.10.012_bib0176","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1182\/blood-2022-159357","volume":"140","author":"Straka","year":"2022","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.clml.2024.10.012_bib0177","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1177\/2040620718775629","article-title":"Update on the role of lenalidomide in patients with multiple myeloma","volume":"9","author":"Holstein","year":"2018","journal-title":"Ther Adv Hematol"},{"issue":"9","key":"10.1016\/j.clml.2024.10.012_bib0178","doi-asserted-by":"crossref","first-page":"e431","DOI":"10.1016\/S2352-3026(17)30140-0","article-title":"Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial","volume":"4","author":"Holstein","year":"2017","journal-title":"Lancet Haematol"},{"issue":"3","key":"10.1016\/j.clml.2024.10.012_bib0179","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S1470-2045(13)70609-0","article-title":"Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data","volume":"15","author":"Palumbo","year":"2014","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.clml.2024.10.012_bib0180","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41408-020-00400-4","article-title":"Effect of autologous hematopoietic stem cell transplant on the development of second primary malignancies in multiple myeloma patients","volume":"11","author":"Rosenberg","year":"2021","journal-title":"Blood Cancer J"},{"issue":"5","key":"10.1016\/j.clml.2024.10.012_bib0181","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.bbmt.2018.01.006","article-title":"Incidence of Second Primary Malignancies after Autologous Transplantation for Multiple Myeloma in the Era of Novel Agents","volume":"24","author":"Sahebi","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"10.1016\/j.clml.2024.10.012_bib0182","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1200\/JCO.2012.41.6180","article-title":"Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma","volume":"31","author":"San Miguel","year":"2013","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.clml.2024.10.012_bib0183","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/S1470-2045(17)30578-8","article-title":"Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial","volume":"18","author":"Dimopoulos","year":"2017","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.clml.2024.10.012_bib0184","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1182\/bloodadvances.2022009138","article-title":"Impact of second primary malignancy post-autologous transplantation on outcomes of multiple myeloma: a CIBMTR analysis","volume":"7","author":"Ragon","year":"2023","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.clml.2024.10.012_bib0185","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/ejh.12478","article-title":"Clinical course and prognosis of non-secretory multiple myeloma","volume":"95","author":"Chawla","year":"2015","journal-title":"Eur J Haematol"},{"issue":"8","key":"10.1016\/j.clml.2024.10.012_bib0186","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.clml.2024.10.012_bib0187","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1093\/jalm\/jfab055","article-title":"Use of a daratumumab-specific immunofixation assay to assess possible immunotherapy interference at a major cancer center: our experience and recommendations","volume":"6","author":"Kirchhoff","year":"2021","journal-title":"J Appl Lab Med"},{"issue":"2","key":"10.1016\/j.clml.2024.10.012_bib0188","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41408-021-00408-4","article-title":"Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee Report","volume":"11","author":"Murray","year":"2021","journal-title":"Blood Cancer J"},{"issue":"18","key":"10.1016\/j.clml.2024.10.012_bib0189","doi-asserted-by":"crossref","first-page":"4691","DOI":"10.1182\/blood-2010-10-299487","article-title":"Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1","volume":"117","author":"Rajkumar","year":"2011","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.clml.2024.10.012_bib0190","doi-asserted-by":"crossref","first-page":"e213","DOI":"10.1016\/j.clml.2018.12.022","article-title":"Immune signatures associated with clonal isotype switch after autologous stem cell transplantation for multiple myeloma","volume":"19","author":"Ye","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"12","key":"10.1016\/j.clml.2024.10.012_bib0191","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.3324\/haematol.2014.111104","article-title":"Secondary monoclonal gammopathy of undetermined significance after allogeneic stem cell transplantation in multiple myeloma","volume":"99","author":"Schmitz","year":"2014","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.clml.2024.10.012_bib0192","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.3324\/haematol.2013.084350","article-title":"Natural history and prognostic impact of oligoclonal humoral response in patients with multiple myeloma after autologous stem cell transplantation: long-term results from a single institution","volume":"98","author":"Tovar","year":"2013","journal-title":"Haematologica"},{"issue":"10","key":"10.1016\/j.clml.2024.10.012_bib0193","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41408-020-00363-6","article-title":"Utility of repeating bone marrow biopsy for confirmation of complete response in multiple myeloma","volume":"10","author":"Tschautscher","year":"2020","journal-title":"Blood Cancer J"},{"issue":"6","key":"10.1016\/j.clml.2024.10.012_bib0194","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1182\/blood.2021011101","article-title":"Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA","volume":"139","author":"Cavo","year":"2022","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.clml.2024.10.012_bib0195","doi-asserted-by":"crossref","first-page":"5988","DOI":"10.1182\/bloodadvances.2020002827","article-title":"A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma","volume":"4","author":"Munshi","year":"2020","journal-title":"Blood Adv"},{"issue":"6","key":"10.1016\/j.clml.2024.10.012_bib0196","doi-asserted-by":"crossref","first-page":"e302","DOI":"10.1016\/S1470-2045(19)30309-2","article-title":"International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders","volume":"20","author":"Hillengass","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2024.10.012_bib0197","unstructured":"American Society of Clinical Oncology (ASCO). ASCO Guidelines Methodology Manual. Available at: https:\/\/www.asco.org\/sites\/new-www.asco.org\/files\/content-files\/practice-and-guidelines\/documents\/2019-Guidelines-Methodology-Manual.pdf. Accessed April 29, 2023."}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024023851?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024023851?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T12:47:44Z","timestamp":1739364464000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265024023851"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":197,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S2152265024023851"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2024.10.012","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"First Line Treatment of Newly Diagnosed Transplant Eligible Multiple Myeloma Recommendations From a Canadian Consensus Guideline Consortium","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2024.10.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}